TY - JOUR
T1 - A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands
AU - de Jong, Evelien J. M.
AU - Geurts, Sandra M. E.
AU - van der Geest, Lydia G.
AU - Besselink, Marc G.
AU - Bouwense, Stefan A. W.
AU - Buijsen, Jeroen
AU - Dejong, Cornelis H. C.
AU - Heij, Lara R.
AU - Koerkamp, Bas Groot
AU - de Hingh, Ignace H. J. T.
AU - Hoge, Chantal
AU - Kazemier, Geert
AU - van Laarhoven, Hanneke W. M.
AU - de Meijer, Vincent E.
AU - Mohammad, Nadia Haj
AU - Strijker, Marin
AU - Timmermans, Karin C. A. A.
AU - Valkenburg-van Iersel, Liselot B. J.
AU - Wilmink, Johanna W.
AU - Tjan-Heijnen, Vivianne C. G.
AU - de Vos-Geelen, Judith
AU - Dutch Pancreatic Cancer Group
PY - 2021/7
Y1 - 2021/7
N2 - Introduction: Ampullary cancer is rare and as a result epidemiological data are scarce. The aim of this population-based study was to determine the trends in incidence, treatment and overall survival (OS) in patients with ampullary adenocarcinoma in the Netherlands between 1989 and 2016.Methods: Patients diagnosed with ampullary adenocarcinoma were identified from the Netherlands Cancer Registry. Incidence rates were age-adjusted to the European standard population. Trends in treatment and OS were studied over (7 years) period of diagnosis, using Kaplan-Meier and Cox regression analyses for OS and stratified by the presence of metastatic disease.Results: In total, 3840 patients with ampullary adenocarcinoma were diagnosed of whom, 55.0% were male and 87.1% had non-metastatic disease. The incidence increased from 0.59 per 100,000 in 1989-1995 to 0.68 per 100,000in 2010-2016. In non-metastatic disease, the resection rate increased from 49.5% in 1989-1995 to 63.9% in 2010-2016 (p < 0.001). The rate of adjuvant therapy increased from 3.1% to 7.9%. In non-metastatic disease, five-year OS (95% CI) increased from 19.8% (16.9-22.8) in 1989-1995 to 29.1% (26.0-31.2) in 2010e2016 (logrank p < 0.001). In patients with metastatic disease, median OS did not significantly improve (from 4.4 months (3.6-5.0) to 5.9 months (4.7-7.1); logrank p = 0.06). Cancer treatment was an independent prognostic factor for OS among all patients.Conclusion: Both incidence and OS of ampullary cancer increased from 1989 to 2016 which is most likely related to the observed increased resection rates and use of adjuvant therapy. (C) 2021 The Authors. Published by Elsevier Ltd.
AB - Introduction: Ampullary cancer is rare and as a result epidemiological data are scarce. The aim of this population-based study was to determine the trends in incidence, treatment and overall survival (OS) in patients with ampullary adenocarcinoma in the Netherlands between 1989 and 2016.Methods: Patients diagnosed with ampullary adenocarcinoma were identified from the Netherlands Cancer Registry. Incidence rates were age-adjusted to the European standard population. Trends in treatment and OS were studied over (7 years) period of diagnosis, using Kaplan-Meier and Cox regression analyses for OS and stratified by the presence of metastatic disease.Results: In total, 3840 patients with ampullary adenocarcinoma were diagnosed of whom, 55.0% were male and 87.1% had non-metastatic disease. The incidence increased from 0.59 per 100,000 in 1989-1995 to 0.68 per 100,000in 2010-2016. In non-metastatic disease, the resection rate increased from 49.5% in 1989-1995 to 63.9% in 2010-2016 (p < 0.001). The rate of adjuvant therapy increased from 3.1% to 7.9%. In non-metastatic disease, five-year OS (95% CI) increased from 19.8% (16.9-22.8) in 1989-1995 to 29.1% (26.0-31.2) in 2010e2016 (logrank p < 0.001). In patients with metastatic disease, median OS did not significantly improve (from 4.4 months (3.6-5.0) to 5.9 months (4.7-7.1); logrank p = 0.06). Cancer treatment was an independent prognostic factor for OS among all patients.Conclusion: Both incidence and OS of ampullary cancer increased from 1989 to 2016 which is most likely related to the observed increased resection rates and use of adjuvant therapy. (C) 2021 The Authors. Published by Elsevier Ltd.
KW - Ampullary cancer
KW - Ampulla of vater
KW - Epidemiology
KW - Survival
KW - Treatment
KW - Trends
KW - PERIAMPULLARY CANCER
KW - ADJUVANT THERAPY
KW - BILIARY-TRACT
KW - BILE-DUCT
KW - CHEMOTHERAPY
KW - PANCREATICODUODENECTOMY
KW - MANAGEMENT
KW - RESECTION
KW - ADENOCARCINOMA
KW - RADIOTHERAPY
U2 - 10.1016/j.ejso.2021.02.028
DO - 10.1016/j.ejso.2021.02.028
M3 - Article
C2 - 33712346
SN - 0748-7983
VL - 47
SP - 1742
EP - 1749
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 7
ER -